The report will be delivered in 2-3 business days.
Banner

Neurodegenerative Disorder Therapeutics Global Market Report 2021 - By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Growth And Change

aboutimg
Purchase Options
Request Sample
Request For Discount
FAQ
Infoimg

Starting Price : $5000.00 $4000.00 | Pages : 175 | Published : March 2021 | SKU CODE : 7605 | Format :


Description Table Of Contents Tables & Figures Market Insights Related Reports

The neurodegenerative disorder therapeutics market consists of sales of neurodegenerative disorder therapeutics products and related services for neurodegenerative disorders. Neurodegenerative disorder is a range of incurable conditions that primarily affect the neurons of human brain and results in progressive degeneration or death of nerve cells. The neurodegenerative disorder therapeutics deals with the manufacturing and development of drugs and treatment that stops or slows down the neurodegenerative processes of diseases such as Parkinson’s, Alzheimer’s, Huntington’s and other neurodegenerative disorders.

The neurodegenerative disorder therapeutics market covered in this report is segmented by indication type into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, other indications. It is also segmented by drug type into n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, others and by distribution into hospital pharmacy, retail pharmacy, online pharmacy.

The global neurodegenerative disorder therapeutics market is expected to grow from $14.08 billion in 2020 to $15.19 billion in 2021 at a compound annual growth rate (CAGR) of 7.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The neurodegenerative disorder therapeutics market is expected to reach $20.15 billion in 2025 at a CAGR of 7%.

Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market. The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age increased to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.

High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials. For instance, 12 of the 42 (28 per cent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics has a negative impact on the market, hindering the growth of the market.

 

Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market in order to increase their capabilities for research and development activities in order to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, from October 2019, Prevail Therapeutics Inc., a USA based biotechnology company and Lonza, a global supplier of pharma & Biotech and specialty ingredients based in Switzerland, collaborated to develop and manufacture gene therapy programs for patients of neurodegenerative diseases. Similarly, Abbevie, a USA based biopharmaceutical company and Voyager Therapeutics, a clinical stage gene therapy company based in USA, underwent a global strategic collaboration to develop and commercialize treatments for Alzheimer’s disease and other tau-related (a protein) neurodegenerative diseases.

In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 alongwith the applications from Pfizer for $75 million. The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS- penetrant regulator that has the potential to treat behavioral and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc., is a multinational pharmaceutical company based in the USA.

Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH.

The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global neurodegenerative disorder therapeutics market is segmented -

1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Table Of Contents

    1. Executive Summary

    2. Neurodegenerative Disorder Therapeutics Market Characteristics

    3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies

    4. Impact Of COVID-19 On Neurodegenerative Disorder Therapeutics

    5. Neurodegenerative Disorder Therapeutics Market Size And Growth

    5.1. Global Neurodegenerative Disorder Therapeutics Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Neurodegenerative Disorder Therapeutics Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Neurodegenerative Disorder Therapeutics Market Segmentation

    6.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Parkinson`s Disease

    Alzheimer`s Disease

    Multiple Sclerosis

    Huntington Disease

    Other Indication Types

    6.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    N- methyl- D- aspartate Receptor

    Selective Serotonin Reuptake Inhibitor

    Dopamine Inhibitors

    Other Drug Types

    6.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    7. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

    7.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

    8.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.3. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Neurodegenerative Disorder Therapeutics Market

    9.1. China Neurodegenerative Disorder Therapeutics Market Overview

    9.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.3. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Neurodegenerative Disorder Therapeutics Market

    10.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.2. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Neurodegenerative Disorder Therapeutics Market

    11.1. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Neurodegenerative Disorder Therapeutics Market

    12.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.2. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Neurodegenerative Disorder Therapeutics Market

    13.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.2. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Neurodegenerative Disorder Therapeutics Market

    14.1. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Neurodegenerative Disorder Therapeutics Market

    15.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview

    15.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.3. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Neurodegenerative Disorder Therapeutics Market

    16.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.2. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Neurodegenerative Disorder Therapeutics Market

    17.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.2. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Neurodegenerative Disorder Therapeutics Market

    18.4. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.5. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Neurodegenerative Disorder Therapeutics Market

    19.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview

    19.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.3. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Neurodegenerative Disorder Therapeutics Market

    20.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.2. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Neurodegenerative Disorder Therapeutics Market

    21.1. North America Neurodegenerative Disorder Therapeutics Market Overview

    21.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.3. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Neurodegenerative Disorder Therapeutics Market

    22.1. USA Neurodegenerative Disorder Therapeutics Market Overview

    22.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.3. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Neurodegenerative Disorder Therapeutics Market

    23.1. South America Neurodegenerative Disorder Therapeutics Market Overview

    23.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.3. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Neurodegenerative Disorder Therapeutics Market

    24.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.2. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Neurodegenerative Disorder Therapeutics Market

    25.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview

    25.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.3. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Neurodegenerative Disorder Therapeutics Market

    26.1. Africa Neurodegenerative Disorder Therapeutics Market Overview

    26.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.3. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

    27.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape

    27.2. Neurodegenerative Disorder Therapeutics Market Company Profiles

    27.2.1. Biogen

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Novartis

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Sanofi

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Teva Pharmaceutical

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Neurodegenerative Disorder Therapeutics Pipeline Analysis

    29. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

    30. Neurodegenerative Disorder Therapeutics Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 27: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 28: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 29: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 31: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 32: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 33: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 34: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 35: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 36: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 37: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 38: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 39: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 40: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 41: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 42: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 43: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 44: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 45: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 46: Biogen Financial Performance
  • Table 47: Pfizer Financial Performance
  • Table 48: Novartis Financial Performance
  • Table 49: Sanofi Financial Performance
  • Table 50: Teva Pharmaceutical Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: China, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: India, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: Japan, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Australia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Indonesia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: South Korea, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Western Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: UK, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 27: Germany, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 28: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 29: France, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 31: Eastern Europe, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 32: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 33: Russia, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 34: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 35: North America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 36: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 37: USA, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 38: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 39: South America, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 40: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 41: Brazil, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 42: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 43: Middle East, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 44: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 45: Africa, Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 46: Biogen Financial Performance
  • Figure 47: Pfizer Financial Performance
  • Figure 48: Novartis Financial Performance
  • Figure 49: Sanofi Financial Performance
  • Figure 50: Teva Pharmaceutical Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Neurophysiology Devices And Equipment Global Market Report 2021 - By Technology (Electromyography (EMG), Electroencephalography (EEG), Electrocorticography (ECoG), Evoked potential (EP)), By End Users (Hospitals, Ambulatory Surgical Centers), By Modality (Standalone, Portable), COVID-19 Growth And Change
View Report
Neurostimulation Devices Global Market Report 2021 - By Product (Implantable Devices, External Devices), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary And Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease), By End User (Hospitals, Rehabilitation Centers, Medical Clinic), By Implantable Devices (Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), By External Devices (Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)), COVID-19 Impact And Recovery
View Report
Interventional Neurology Devices And Equipment Global Market Report 2021 - By Type (Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices), By End-User (Hospitals, Neurology Clinics, Ambulatory Care Centers), Aneurysm Coiling & Embolization Devices By Type (Embolic Coils, Flow Diversion Devices, Liquid Embolic Devices), Angioplasty Devices By Type (Carotid Artery Stents, Embolic Protection Systems), Support Devices By Type (Micro Guide Wires, Micro Catheters), Neurothrombectomy Devices By Type (CLOT Retrieval Devices, Suction And Aspiration Devices, Snares), COVID-19 Impact And Recovery
View Report
Neurosurgery Devices And Equipment Global Market Report 2021 - By Device Type (Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Neurosurgery Surgical Power Tools), By Surgery Type (Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery), By End User (Hospitals, Ambulatory Surgical Centers), COVID-19 Impact And Recovery
View Report
Brain And Neuroimaging Devices Global Market Report 2021 - By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG)), By End-User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), By Application (Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders), COVID-19 Growth And Change
View Report
Radiopharmaceuticals Global Market Report 2021 - By Type (Diagnostic, Therapeutic), By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology, Nephrology), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes), COVID 19 Growth And Change
View Report
Neurology Devices Global Market Report 2021 - By Type (Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices), By End User (Hospitals And Clinics, Diagnostic Laboratories), By Type of Expenditure (Public, Private), By Product (Instruments/Equipment, Disposables), COVID-19 Impact And Recovery
View Report
Medical Devices Market 2021 - By Type Of Device (In-Vitro Diagnostics, Dental Equipment, Ophthalmic Devices, Diagnostic Equipment, Hospital Supplies, Cardiovascular Devices, Surgical Equipment, Patient Monitoring Devices, Orthopedic Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices), By Type Of Expenditure (Public, Private), By End-User (Hospitals And Clinics, Homecare, Diagnostics Centers) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)